4-异丙硫基苯硼酸 | 380427-38-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 4-异丙硫基苯硼酸
• 中文别名: 4-(异丙基硫代)苯硼酸；4-异丙硫基苯基硼酸
• 英文名称: (4-(isopropylthio)phenyl)boronic acid
• 英文别名: 4-Isopropylthiophenylboronic acid；(4-propan-2-ylsulfanylphenyl)boronic acid
• CAS: 380427-38-3
• 化学式: C₉H₁₃BO₂S
• mdl: MFCD03411947
• 分子量: 196.078
• InChiKey: FYJDSWBEPMIWEC-UHFFFAOYSA-N

物化性质

• 熔点：
  82-88°C
• 沸点：
  347.2±44.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.84
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  65.8
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Isopropylthiophenylboronic acid
Product Name:
Synonyms: 4-(Isopropylthio)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Isopropylthiophenylboronic acid
Ingredient name:
CAS number: 380427-38-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H13BO2S
Molecular weight: 196.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-异丙硫基苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 NiBr2*diglyme 、 三乙胺盐酸盐 、 potassium carbonate 、 4,4'-二叔丁基-2,2'-二吡啶 、 sodium iodide 、 锌 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 20.0h， 生成 6,6-difluoro-5-(4-(isopropylthio)phenyl)-2-methylhex-5-en-2-ol
  参考文献：
  名称：

  通过三氟甲基烯烃与环氧化物的镍催化的烯丙基脱氟还原性交叉偶联反应合成宝石二氟烯烃。

  摘要：

  已经开发了三氟甲基烯烃与环氧化物的镍催化的脱氟还原性交叉偶联。发现各种取代的三氟甲基烯烃和环氧化物是合适的反应底物。该反应通过在温和的反应条件下三氟甲基烯烃的烯丙基脱氟交叉偶联实现了C（sp3）-C（sp3）键的构建。该方法与各种敏感的官能团高度兼容，从而提供了多种功能化的含宝石二氟烯烃的醇化合物。

  DOI：

  10.1039/d0ob00535e
• 作为产物：
  描述：

  1-溴-4-(丙烷-2-基硫烷基)苯 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 、 氢氧化钾 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 0.5h， 以90%的产率得到4-异丙硫基苯硼酸
  参考文献：
  名称：

  [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP
  [FR] MODULATEURS SELECTIFS DES RECEPTEURS OESTROGENIQUES CONTENANT UN GROUPE PHENYLSULFONYLE

  摘要：

  本发明涉及式I的选择性雌激素受体调节剂或其药用酸盐加合物；例如，用于治疗子宫内膜异位症和/或子宫平滑肌瘤。

  公开号：

  WO2004009086A1

文献信息

• Regioselective Synthesis and Photophysical and Electrochemical Studies of 20-Substituted Cyanine Dye-Purpurinimide Conjugates: Incorporation of Ni^IIinto the Conjugate Enhances its Tumor-Uptake and Fluorescence-Imaging Ability
  作者：Manivannan Ethirajan、Ping Chen、Tymish Y. Ohulchanskyy、Lalit N. Goswami、Anurag Gupta、Avinash Srivatsan、Mahabeer P. Dobhal、Joseph R. Missert、Paras N. Prasad、Karl M. Kadish、Ravindra K. Pandey

  DOI：10.1002/chem.201203867

  日期：2013.5.17

  approach to the synthesis of a variety of meso‐substituted purpurinimides. The reaction of meso‐substituted purpurinimide with N‐bromosuccinimide regioselectively introduced a bromo functionality at the 20‐position, which on further reaction with a variety of boronic acids under Suzuki reaction conditions yielded the corresponding meso‐substituted analogues. Interestingly, the free base and the metalated

  我们在这里报告了一种简单有效的方法来合成各种内消旋取代的紫嘌呤亚胺。的反应内消旋-取代紫红素与Ñ溴代琥珀酰亚胺区域选择性引入到20位，将其用各种Suzuki反应条件下，硼酸进一步反应得到相应的溴功能内消旋取代的类似物。有趣的是，游离碱和金属化类似物在光敏功效（PDT）和肿瘤成像能力方面显示出显着差异。例如，游离碱偶联物在体外具有显着的PDT功效，但在荷瘤小鼠中肿瘤亲和力有限，而相应的Ni II该衍生物不会产生任何细胞杀伤作用，但在注射后24、48和72 h，以0.3μmolkg -1的剂量显示出优异的肿瘤成像能力。Ni II类似物的PDT功效有限可能是由于其无法产生单线态氧，而单线态氧是PDT中杀死细胞所需的关键细胞毒剂。根据DMSO中的电化学和光谱电化学数据，游离碱和相应的Ni II的第一次单电子氧化（0.52 V vs. SCE）和第一次单电子还原（-0.57-0.67 V vs. S
• [EN] PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHÉNYLALCANOÏQUE EN TANT QU'AGONISTES DU RPG
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2013128378A1

  公开（公告）日：2013-09-06

  The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).

  本发明涉及苯基烷酸衍生物（公式(I)的化合物）；及其同位素形式、立体异构体、互变异构体和所有比例的混合物，或其药物可接受的盐、药物可接受的溶剂化物、前药、多态性、N-氧化物、S-氧化物或羧酸的等排体。本发明还涉及制备公式(I)化合物的方法和包含一个或多个公式(I)化合物的药物组合物。所述化合物和药物组合物作为GPR（G蛋白偶联受体）激动剂，特别是作为GPR40激动剂，并且可用于治疗由GPR40介导的疾病或状况。本发明进一步涉及一种治疗由GPR40介导的疾病或状况的方法，包括向需要治疗的受试者施用治疗有效量的公式(I)化合物。
• [EN] INHIBITORS OF HUMAN ATGL<br/>[FR] INHIBITEURS DE L'ATGL HUMAIN
  申请人：KARL FRANZENS UNIV GRAZ

  公开号：WO2021019051A1

  公开（公告）日：2021-02-04

  The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

  本发明涉及新型抑制脂肪甘油三酯脂肪酶（ATGL）的抑制剂，其对人类ATGL（hATGL）具有改善的抑制活性，以及包含这些抑制剂的药物组合物，及其治疗用途，特别是在治疗或预防脂质代谢紊乱方面的用途，包括例如肥胖、非酒精性脂肪肝病、2型糖尿病、胰岛素抵抗、葡萄糖不耐症、高甘油三酯血症、代谢综合征、心脏和骨骼肌脂肪变性、先天性全身性脂肪营养不良、家族性部分脂肪营养不良、获得性脂肪营养不良综合征、动脉粥样硬化或心力衰竭。
• A practical and general ipso iodination of arylboronic acids using N-iodomorpholinium iodide (NIMI) as a novel iodinating agent: mild and regioselective synthesis of aryliodides
  作者：R. H. Tale、G. K. Toradmal、V. B. Gopula

  DOI：10.1039/c5ra18820b

  日期：——

  A mild and efficient protocol for the ipso-iodination of aryl boronic acids using N-iodomorpholinium iodide (NIMI) generated in situ from morpholine and molecular iodine as a novel iodinating agent has been developed. The addition of a catalytic amount of copper iodide found to promote rate enhancement of the iodination reaction and dramatic increase in the yield depending upon the nature of the boronic

  为A温和高效的协议本位的芳基硼酸使用-iodination Ñ -iodomorpholinium碘（NIMI）产生原位从吗啉和分子碘作为一种新型的碘化剂已经研制成功。观察到添加催化量的碘化铜可以促进碘化反应的速率提高，并且取决于硼酸的性质，可以显着提高产率。机理研究表明，取决于基材的性质，经典的ipso取代或铜催化的碘脱硼化途径总体上主导了目前的碘化反应。诸如温和的反应条件，操作简便，高至优异的收率，优异的官能团相容性和较低的催化剂载量等特征使该方法潜在地可用于有机合成中。
• NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS
  申请人：MetCalf, III Chester A.

  公开号：US20100184649A1

  公开（公告）日：2010-07-22

  The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against Clostridium difficile.

  本发明涉及新型脂肽化合物，这些化合物的药物组合物以及使用这些化合物作为抗菌化合物的方法。本发明的化合物特别适用于对抗各种细菌，包括耐药菌株。这些化合物可用作抗Clostridium difficile的抗菌剂。